TScan Therapeutics (TCRX) Cash from Operations (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Cash from Operations data on file, last reported at 24279000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 35.4% year-over-year to 24279000.0 in Q1 2026; TTM through Mar 2026 was 122012000.0, a 2.41% decrease from a year earlier, with the FY2025 full-year figure at 135319000.0, down 22.1% from the prior year.
• Cash from Operations for Q1 2026 stood at 24279000.0, up from 32002000.0 in the prior quarter.
• Over the last five years, Cash from Operations for TCRX reached as high as 8017000.0 in Q3 2023 and fell as low as 37586000.0 in Q1 2025.
• Historically, Cash from Operations has averaged 23428294.12 across 5 years, with a median of 24279000.0 in 2026.
• Across the five-year window, Cash from Operations surged 147.15% in 2023 and plunged 448.24% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 16010000.0 in 2022, then tumbled by 48.44% to 23766000.0 in 2023, then retreated by 15.34% to 27412000.0 in 2024, then retreated by 16.74% to 32002000.0 in 2025, then gained by 24.13% to 24279000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 24279000.0 in Q1 2026, 32002000.0 in Q4 2025, and 32464000.0 in Q3 2025.